Screening for Chronic Liver Diseases in General Population

Condition(s) studied

Investigational drug(s) / intervention(s)

Blood sample then fibroscan: The patient takes a blood test if none less than 6 months old is available, including a complete blood count (CBC) and a hepatic check. The FIB-4 score will be calculated from this blood test. If the result of the FIB-4 test is greater than 1.3 the person will be contacted by the SELHV (Service Expert de Lutte contre les Hépatites Virales) of the University Hospital of Montpellier in order to schedule, if she wishes, a second non-invasive screening examination of liver fibrosis by Fibroscan.

Study summary

Improving the care of patients with liver diseases in primary care and will allow patients with chronic liver disease to benefit from a course appropriate care.

Eligibility

Primary outcome measure(s)

• Evaluation of the liver fibrosis screening acceptability (FIB-4) — During the inclusion assessment at day 1 (Visit 0)
  percentage of patients who agreed to a FIB-4 blood test among all included patients offered screening.
• Evaluation of the liver fibrosis screening acceptability (FIB-4 and Fibroscan) — During the inclusion assessment at day 1 (Visit 0) and at 1 month (visit 1)
  percentage of patients who agreed to a FIB-4 blood test FIB-4 followed by Fibroscan (if FIB-4 score\>1.3) among all included patients offered screening.

Trial sites (1)

More University Hospital, Montpellier trials in France

Other trials for the same condition